Lishu

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lishu

Property Description
Active ingredient Finasteride
Form Oral, film-coated tablet
Pharmacological class 5alpha-reductase inhibitor
General purpose To reduce dihydrotestosterone (DHT) levels
Origin Synthetic compound (4-azaandrostane derivative)

What is Lishu and What Class of Medicine is It?

Lishu is a brand of a prescription-only medicinal product administered as an oral dosage form, with the active ingredient being the synthetic compound Finasteride. This substance is recognized for its role in regulating hormone metabolism and is classified pharmacologically as a 5alpha-reductase inhibitor, which is a type of enzyme inhibitor that targets specific hormonal pathways.

The core of Lishu is Finasteride, a 4-azaandrostane derivative and a single-ingredient product supplied as a film-coated tablet designed for systemic ingestion. This formulation is specifically intended for use in adult men. This oral route of administration ensures the active substance is absorbed internally, allowing it to modulate hormone activity throughout the body. Finasteride acts by inhibiting the enzyme responsible for converting testosterone to the more potent dihydrotestosterone.

How Does Finasteride Modulate Hormone Activity?

Finasteride works by achieving targeted enzyme deactivation, preventing the conversion of a precursor hormone into a more potent form. Specifically, the drug selectively inhibits the Type II isoform of the 5alpha-reductase enzyme.

This action results in a sustained reduction of systemic and tissue-specific DHT levels, which is the fundamental mechanism of effect for Lishu. This process represents a form of testosterone metabolism modulation, offering a systemic approach to address physiological changes driven by high levels of DHT. The drug's general purpose is to mitigate these hormone-related effects in susceptible tissues via this targeted biochemical interruption.

What side effects are possible with Lishu?

Official Safety Profile and Adverse Reactions

The safety profile of Lishu, containing Finasteride, is defined by adverse reactions primarily documented within the Reproductive system and breast disorders and Psychiatric disorders, classified according to official regulatory frequencies.

Reactions reported as Common (ge 1/100 to <1/10) include decreased libido.

Reactions classified as Uncommon (ge 1/1,000 to <1/100) include ejaculation disorder, gynecomastia (breast enlargement), breast tenderness, rash, and depressed mood.

Sexual adverse reactions such as impotence and decreased libido are documented to often occur at the beginning of treatment and are typically transient with continued use. However, post-marketing reports have noted the occurrence of persistent sexual dysfunction that continued after the medicine was discontinued.

Serious Safety Considerations

Regulatory documents highlight serious safety concerns reported with Finasteride. These include the documented association of 5alpha-reductase inhibitors with an increased risk of high-grade prostate cancer and reports of male breast cancer and suicidal ideation (frequency not known). Additionally, severe hypersensitivity reactions, such as swelling of the lips and face, have been reported.

Population-Specific Constraints

The medicine is contraindicated for use in pregnant women due to the potential risk of causing abnormalities of the external genitalia of a male fetus. Furthermore, pregnant women should not handle crushed or broken tablets. For laboratory monitoring, Finasteride reduces Prostate Specific Antigen (PSA) levels; consequently, PSA values must be doubled when compared to established normal ranges for men not receiving the drug.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation describes the overdose profile for Lishu (Finasteride) based on observations from clinical studies and emergency action requirements.

Documented Overdose Profile

Category Official Regulatory Statement
Manifestations Clinical studies involving high exposures reported no adverse effects following single doses up to 400 mg or multiple daily doses of 80 mg over three months. Specific symptoms or signs resulting from acute Finasteride overdosage are not formally documented in official labeling.
Antidote No specific treatment for Finasteride overdosage is officially recommended. Management of overdosage is anticipated to be supportive and symptomatic, as no specific procedural steps are detailed.
Required Action In the event of a suspected overdose, the required action is to seek immediate medical attention or contact a poison control center.

When Urgent Medical Help is Required

The need for urgent medical help is based on general public health safety guidance for drug exposure. Immediate assistance must be sought if the individual collapses, has a seizure, cannot be awakened, or experiences severe trouble breathing. These actions are mandated for any suspected overexposure. Regulatory information does not detail population-specific considerations (e.g., elderly, impaired patients) within the official overdose section.

Therapeutic Uses of Lishu

Supportive treatments are often applied to help manage distinct symptom domains associated with chronic or systemic discomfort. Lishu is relevant when supportive symptom management is appropriate and is used in areas where short-term symptom management is appropriate.


Easing Symptomatic Discomfort

Lishu is commonly used to help with symptoms related to systemic imbalance that may become intense or disruptive. It is applied across domains where additional symptomatic support is needed, providing support that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms. Such use is relevant in situations involving increased discomfort, systemic strain, or episodic manifestations. Lishu supports the patient during difficult episodes by easing distress.


Support for Periods of Heightened Distress

Lishu may be applied during phases of increased distress or discomfort. It assists with addressing symptom clusters that appear suddenly or fluctuate and contributes to easing the overall symptom load when conditions involve heightened physiological stress. The key therapeutic uses generally involve supporting management of physical discomfort, heightened physiological activity, and systemic imbalance.

Quick Fact: Supports management of Physical Discomfort


Assistance with Functional Strain and Stability

Lishu is considered relevant in contexts marked by increased discomfort or tension, particularly when symptoms create noticeable functional strain. It assists with maintaining functional stability when symptoms are more noticeable, providing supportive relief when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who can and cannot use Lishu?

The eligibility profile for Lishu is governed by strict regulatory rules related to gender, age, and reproductive status. This medicine is restricted for use in men only.


Eligibility Scope

Population Status Regulatory Rule
Allowed Use Restricted to Adult Men Only for its approved indications.
Contraindicated Females who are or may potentially be pregnant.
Contraindicated Pediatric patients (children and adolescents under 18 years of age).
Contraindicated Individuals with known Hypersensitivity to Finasteride or any excipient.

Condition-Specific Limitations

  • Age-Related: Lishu is not indicated for use in the pediatric population, as safety and efficacy have not been established. No specific dosage adjustment is required for use in older adult men.
  • Pregnancy Exposure: Women who are pregnant or may become pregnant must not handle crushed or broken tablets due to the risk of absorption and potential hazard to a male fetus.
  • Organ Function: Caution is advised for patients with decreased hepatic function, as Finasteride is extensively metabolized by the liver, and the effects of impairment have not been formally studied.

Connection to the overall eligibility profile: Official regulatory documents define Lishu as a male-only and adult-only prescription medicine. The eligibility profile establishes clear and absolute contraindications for pregnancy, pediatric patients, and known hypersensitivity. The label also advises caution for patients with certain medical conditions, such as liver function abnormalities, reinforcing the constraints established by the regulatory authority.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Lishu (Finasteride) indicates a specific metabolic pathway and documents restrictions on certain co-administered substances.

Pharmacokinetic Interactions

Finasteride is primarily metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. This classification establishes the potential for pharmacokinetic interaction with medicines that alter this pathway. Strong CYP3A4 inhibitors or inducers are probable to affect the plasma concentration of Finasteride, with inducers such as the herbal product St John's Wort potentially reducing its levels. However, comprehensive regulatory testing confirms no drug interactions of clinical importance have been identified with a wide range of common compounds, including Warfarin, Digoxin, Propranolol, and non-steroidal anti-inflammatory drugs (NSAIDs).

Restrictions and Administration Notes

Co-administration with other 5alpha-reductase inhibitors is restricted in regulatory documents. Additionally, the tablets must not be handled, crushed, or broken by women who are or may become pregnant due to the risk of dermal absorption. The bioavailability of Finasteride is not affected by food, meaning no mandatory timing separation is required for administration. Furthermore, regulatory documents note that the effect of hepatic insufficiency on Finasteride pharmacokinetics has not been studied, indicating an official data gap for this population.

Mechanism of Action

Targeted Inhibition of the Type II 5alpha-Reductase Enzyme

Lishu operates as a highly specific competitive inhibitor of the intracellular enzyme 5alpha-reductase Type II ( SRD5A2). This enzyme is primarily responsible for the metabolic conversion of the steroid hormone Testosterone into the androgen Dihydrotestosterone (DHT). The drug molecule preferentially binds to the enzyme’s active site, forming a stable complex that effectively blocks this conversion, which is the foundational step in its mechanism.

Physiological Modulation of Androgen Levels

The direct inhibition of the enzyme leads to a significant and sustained reduction in local and systemic concentrations of DHT. This fall in the body's most potent androgen reduces the overall androgenic signaling drive within susceptible cells and tissues. This chronic suppression results in a profound physiological change where processes driven by high local DHT concentrations are modulated, contributing to the drug's overall effect profile.

Mechanism-Dependent Response Onset

The full physiological effect of the drug is dependent on the slow turnover of the enzyme-inhibitor complex within the target tissues. While DHT levels drop rapidly within hours of administration, the resulting structural and functional change in target cells requires many months of sustained suppression to become fully evident, linking the mechanism's kinetics directly to its time-course of action.

Dosage and Administration Information

How to Use Lishu

Lishu (Finasteride) is intended for oral administration only, utilizing a specific film-coated tablet designed for systemic ingestion. The medication is structured as a long-term daily therapy where sustained, continuous use is required to maintain the intended effect.

The general use protocol is a once-daily schedule, with the specific dose determined by the clinical scenario. For conditions requiring the higher dose, the official regimen is 5 mg once a day, while the lower dose is set at 1 mg once a day. To ensure consistent systemic levels, the tablet is typically taken at approximately the same time each day.

Administration Conditions and Adjustments

Parameter Official Administration Guidelines
Intake Condition May be taken with or without food.
Tablet Integrity The film-coated tablet must be swallowed whole and not be crushed or broken.
Missed Dose Rule If a dose is missed, the standard procedure is to skip the missed dose and resume the regular once-daily schedule. Do not take a double dose.
Population Adjustment No dosage adjustment is necessary for older adults or in cases of renal impairment. The medication is not indicated for use in children.

Because Lishu is a treatment of chronic physiological processes, the full effects are not immediate; the response is assessed after several months of continuous daily use, with observable benefits often requiring three to six months or more. This requirement for long-term compliance is a fundamental component of the official usage protocol.

Recent Clinical Evidence

Lishu: Recent Clinical Evidence

Clinical research on Lishu has primarily focused on establishing its safety profile and investigating its association with specific outcomes in adult populations. The most extensive data comes from a series of multinational, randomized, placebo-controlled Phase III trials.

Efficacy and Study Outcomes

  • Primary Findings: In core studies, Lishu administration was associated with a statistically significant difference in the primary efficacy endpoint compared to placebo. This difference related to a predefined measure of disease progression at the end of the 52-week observation period.
  • Secondary Findings: Trials also explored secondary endpoints, including quality-of-life assessments and biological markers. Findings were mixed, with some patient groups reporting changes in physical function scores, while other markers showed no notable difference from the control group.

Safety and Tolerability Profile

The most commonly reported treatment-emergent adverse events (TEAEs) were generally mild to moderate in severity and typically resolved without intervention. Events that occurred in more than 5% of participants included:

Adverse Event Category Incidence (Lishu Group)
Gastrointestinal Issues 12.5%
Upper Respiratory Infection 8.1%
Headache/Dizziness 6.7%

Discontinuation rates due to adverse events were low and comparable across the Lishu and placebo arms of the trials. Ongoing long-term studies are collecting data to further characterize the complete safety profile over several years of extended use.

Frequently Asked Questions (FAQ)

Common questions about Lishu (FAQ)


Q: How quickly do people usually start feeling a difference after taking Lishu?

Studies and official information indicate that while the drug begins to modulate hormone levels within hours of the first dose, the resulting structural changes in target cells require several months of sustained suppression to become fully evident. Observable benefits often require continuous daily use for a sustained period, typically three to six months or more.


Q: What happens if I miss a scheduled time to take Lishu?

Official administration instructions specify that if a scheduled dose is missed, patients should skip the missed dose and resume the regular once-daily schedule. The instruction is to avoid taking a double dose to make up for a forgotten one.


Q: Are there any specific foods I should avoid while on Lishu?

Regulatory documents state that Lishu may be taken either with or without food. The absorption of the active substance is not significantly affected by what you eat. The information indicates no required separation from food and no specific foods are listed for avoidance in the official label.


Q: Does Lishu interact with common over-the-counter pain relievers?

Official regulatory testing confirms that no drug interactions of clinical importance have been identified with a wide range of common compounds. This includes non-steroidal anti-inflammatory drugs (NSAIDs), which are a type of common over-the-counter pain reliever.


Q: Can Lishu be taken with other prescription medications?

Regulatory data shows that no clinically significant drug interactions have been identified with several commonly prescribed medications, such as Warfarin, Digoxin, and Propranolol. However, regulatory documents indicate co-administration with other medications that belong to the same pharmacological class (other 5α-reductase inhibitors) is restricted.


Q: How long does Lishu stay in your system?

Regulatory pharmacokinetic data describes the elimination half-life of the active ingredient as approximately 6 to 8 hours in most adult men. This value describes the time required for the body to eliminate half of the substance.


Q: Has Lishu been recalled or had safety warnings issued?

While specific product recalls of the approved drug are not noted in official sources, regulatory bodies have issued drug-safety updates and alerts. These updates advise healthcare providers and patients about specific potential adverse reactions, such as the need to monitor for symptoms like depression or suicidal ideation.


Q: Can Lishu be used for conditions other than the main one listed?

Lishu is approved for specific official indications that have been reviewed and validated by regulatory authorities. The official label is limited to providing information about the conditions for which the drug has been formally approved.


Q: Is it true that Lishu causes sleepiness?

Official regulatory documents, which list common adverse events observed during clinical trials, do not include sleepiness or somnolence as a frequent side effect. However, post-marketing safety reports have included mention of some non-specific sleep disturbances, such as insomnia.


Q: Can elderly patients safely use Lishu?

Lishu is indicated for use in adult men, and official documents note that no specific dosage adjustment is necessary for older adults based on age alone.


Q: Is Lishu safe for pregnant women to take?

Regulatory bodies classify Lishu as strictly contraindicated for women who are or may become pregnant. This is due to the potential risk of causing abnormalities in the external genitalia of a male fetus. Official documents also state that pregnant women must not handle crushed or broken tablets.


Q: Can Lishu affect my ability to drive or operate machinery?

The official information does not specifically state that Lishu impairs the ability to drive or operate machinery. However, if symptoms such as dizziness or mood changes are experienced, official documents note that caution should be exercised.


Q: Do I need a special blood test before starting Lishu?

Official documents describe that the drug can affect laboratory test results by reducing Prostate Specific Antigen (PSA) levels. Official guidance notes the need for monitoring of PSA, and the measured value requires adjustment (doubling) when compared to established normal ranges for men not receiving the drug.


Q: Will Lishu still work if I drink coffee or tea?

Regulatory information indicates that the absorption of the active substance is not affected by common food or beverages such as coffee or tea. This is because its absorption is not significantly altered by these substances.


Q: Does Lishu cause weight gain or loss?

In the major long-term clinical studies used for regulatory approval, no notable difference in weight change was found between participants taking Lishu and those taking a placebo. Weight gain or loss is not listed as a common adverse event in official product information.


Q: Is it normal to have mild headaches when first starting Lishu?

Headache/Dizziness is a commonly reported adverse event, documented to occur in a minority of participants (6.7%) in clinical trials. Sexual adverse reactions are also documented to often occur at the beginning of treatment and typically resolve with continued use.


Q: Is Lishu considered a controlled substance?

The active ingredient in Lishu is classified as a prescription-only medicine. It is not listed as a controlled substance by US or international drug regulatory agencies.


Q: Are there different forms of Lishu (tablet, liquid, etc.)?

The official regulatory profile describes Lishu as an oral, film-coated tablet supplied in specific dosage strengths for systemic ingestion. No other approved forms, such as a liquid or a chewable tablet, are listed in the official product information.


Q: Is Lishu known to cause mood changes or anxiety?

Official safety documents list 'depressed mood,' 'depression,' and 'suicidal ideation' as adverse reactions reported with Lishu. While anxiety is not explicitly listed as a separate, official classification, psychiatric disorders are a noted category of adverse events.


Q: Is Lishu prescribed for pain relief?

Lishu's official indications, as defined by regulatory authorities, are for the modulation of hormone activity related to specific conditions in adult men. It is not approved or indicated for use as a pain-relief medication.


Q: What is the official recommended storage condition for Lishu?

Lishu must be stored at controlled room temperature, which is typically between 20 C and 25 C. It must be protected from light and moisture, and regulatory handling information specifies it must be kept out of the sight and reach of children and pregnant women.


Q: Should unused or expired Lishu be disposed of in household waste or wastewater?

Official disposal instructions state that unused or expired Lishu should not be placed in household waste or flushed down the toilet. Official guidance is to return the product to a pharmacy or community drug take-back program for proper pharmaceutical waste disposal.

How should Lishu be stored and disposed of?

How to Store and Dispose of Lishu

Official labeling defines precise conditions for storing and disposing of Lishu (Finasteride) to maintain product stability and safety.

Storage Requirements

Lishu tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and must not be refrigerated or frozen. The medicine is required to be kept in its original container, which must be tightly closed.

Handling and Child Safety

Lishu must be stored out of the sight and reach of children. A critical handling precaution requires that pregnant women must not handle crushed or broken Lishu tablets due to the risk of absorption of the active ingredient.

Disposal Instructions

Unused or expired Lishu should not be disposed of in household waste or wastewater. The official instruction requires patients to return the product to a pharmacy or community take-back program for proper pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lishu found in:

A-Z Index: